Avadel Pharmaceuticals Announces Restructuring to Focus on FT218 Cli...
02/07/19
Avadel Pharmaceuticals Announces Restructuring to Focus on FT218 Clinical Development Program Nasdaq
Company cost structure expected to be reduced by $70 to $75 million in 2019–. -Approximately $100 million in cash and marketable securities at.
[more]